Legal & General Group
CNTX icon

Legal & General Group’s Context Therapeutics CNTX Stock Holding History

Legal & General Group’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.03K Buy
+9,074
New +$18.4K ﹤0.01% 3376

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Legal & General Group's CNTX Position: Q2 2026 in Review

Legal & General Group opened a new position in Context Therapeutics (CNTX) in Q2 2026: 9,074 shares worth $5.03K. The stake represents ﹤0.01% of the portfolio and ranks #3376 among its holdings.

79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Legal & General Group held 9,074 shares of Context Therapeutics worth $5.03K as of Q2 2026.
  • Context Therapeutics was a new Legal & General Group position in Q2 2026.
  • Context Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3376 holding.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.